CTLA4 and central nervous system cancer: It should be noted that when comparing the expression profiles of the low- and high-risk groups with the expression profiles of glioma patients who had responded to immunotherapies in SubMap modules, the high-risk group showed a potential response to anti-PD-1 and anti-CTLA4 therapy (Bonferroni-corrected P < 0.05; Fig. 4F).